Tekla Life Sciences Investors Fundamental Analysis (NYSE: HQL)
Tekla Life Sciences Investors Fundamental Analysis (NYSE: HQL)
Tekla Life Sciences Investors (NYSE: HQL) shows moderate financial fundamentals with a PE ratio of 3.19, profit margin of 3.32%, and ROE of 36.89%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 65.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze HQL's fundamental strength across five key dimensions:
Efficiency Score
ExcellentHQL demonstrates superior asset utilization.
Valuation Score
ExcellentHQL trades at attractive valuation levels.
Growth Score
WeakHQL faces weak or negative growth trends.
Financial Health Score
ExcellentHQL maintains a strong and stable balance sheet.
Profitability Score
WeakHQL struggles to sustain strong margins.
Key Financial Metrics
Is HQL Expensive or Cheap?
P/E Ratio
HQL trades at 3.19 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, HQL's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Tekla Life Sciences Investors at 1.17 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.30 times EBITDA. This is generally considered low.
How Well Does HQL Make Money?
Net Profit Margin
For every $100 in sales, Tekla Life Sciences Investors keeps $3.32 as profit after all expenses.
Operating Margin
Core operations generate 3.32 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $36.89 in profit for every $100 of shareholder equity.
ROA
Tekla Life Sciences Investors generates $35.18 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Tekla Life Sciences Investors generates limited operating cash flow of $-2.49M, signaling weaker underlying cash strength.
Free Cash Flow
Tekla Life Sciences Investors generates weak or negative free cash flow of $-2.49M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.08 in free cash annually.
FCF Yield
HQL converts -0.38% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
3.19
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.002
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.17
vs 25 benchmark
P/S Ratio
Price to sales ratio
10.97
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.58
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.37
vs 25 benchmark
ROA
Return on assets percentage
0.35
vs 25 benchmark
ROCE
Return on capital employed
0.35
vs 25 benchmark
How HQL Stacks Against Its Sector Peers
| Metric | HQL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 3.19 | 21.07 | Better (Cheaper) |
| ROE | 36.89% | 647.00% | Weak |
| Net Margin | 331.92% | -1594.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.90 | Strong (Low Leverage) |
| Current Ratio | 2.58 | 912.43 | Strong Liquidity |
| ROA | 35.18% | -579.00% (disorted) | Strong |
HQL outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Tekla Life Sciences Investors's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical